Chief Executive Officer
Aetion
Carolyn Magill is the CEO of Aetion, the digital health leader with an analytics platform and services transforming real-world data into evidence on which clinical interventions work best, for whom and how much we should pay for them. During her 7 year tenure, Aetion has raised over $200M in capital from investors including Warburg Pincus and NEA and grown from start-up to market leader with global customers across regulatory, life sciences and payer sectors. Previously, Carolyn held leadership roles in three companies central to the shift from volume to value in health care. At UnitedHealth, she led Medicare Special Needs Plans nationally, and was COO of the NJ Medicaid health plan. As EVP at Evolent Health from early days through IPO, Carolyn led the team establishing value-based contracts on behalf of health systems and built provider-led health plans. As CEO of Remedy Partners (now part of CVS), she led the premier provider of software and services for Medicare bundled payment programs.
Carolyn has an MBA in health care management from Wharton and a BA from Harvard. She has served on the boards of the National Academy for State Health Policy (NASHP) and Parity.org, advancing gender and racial equity in business leadership. She has been recognized by EY, Goldman Sachs and Crain’s New York for her leadership in health care.